

010.21
A62
MINISTRY OF HEALTH OF THE REPUBLIC OF MOLDOVA

NICOLAE TESTEMIȚANU STATE UNIVERSITY OF MEDICINE
AND PHARMACY

OLEG ZĂNOAGĂ, VALENTIN TOPALO,
DUMITRU ȘCERBATIUC, DUMITRU SÎRBU,
ILIE SUHARSCHI, MIHAI CEBOTARI,
NICOLAE CHELE

ANTITHROMBOTIC TREATMENT – A RISC FACTOR IN ORAL SURGERY



CHIȘINĂU, 2021

616.31
AG2

MINISTRY OF HEALTH OF THE REPUBLIC OF MOLDOVA
NICOLAE TESTEMIȚANU STATE UNIVERSITY OF MEDICINE
AND PHARMACY

OLEG ZĂNOAGĂ, VALENTIN TOPALO, DUMITRU ȘCERBATIUC,
DUMITRU SÎRBU, ILIE SUHARSCHI, MIHAI CEBOTARI,
NICOLAE CHELE

ANTITHROMBOTIC TREATMENT – A RISC FACTOR IN ORAL SURGERY

766773

UNIVERSITATEA DE STAT DE MEDICINĂ ȘI FARMACIE
„NICOLAE TESTEMIȚANU”
BIBLIOTECA
ȘTIINȚIFICĂ MEDICALĂ

5L.3

CHIȘINĂU

Centrul Editorial-Poligrafic *Medicina*

2021

CONTENTS

PREFACE	5
INTRODUCTION	6
<i>CHAPTER 1</i>	9
BASES OF PHYSIOLOGICAL HEMOSTASIS	9
1.1. Physiological hemostasis. Definition. Classification. The components of physiological hemostasis.....	9
1.2. Primary (thrombo-vascular) hemostasis.....	10
1.3. Secondary (plasmatic) hemostasis.....	15
1.4. Antithrombotic mechanisms.....	20
1.4.1. The anticoagulant system.....	20
1.4.2. The fibrinolytic system.....	22
1.5. Blood tests to determine hemostatic disorders.....	24
1.5.1. Blood tests to determine thrombo-vascular changes.....	24
1.5.2. Tests to determine blood clotting disorders.....	25
1.5.3. Tests to determine anticoagulation disorders.....	26
1.5.4. Tests to assess the fibrinolytic system.....	26
<i>CHAPTER 2</i>	27
PHARMACOLOGICAL CHARACTERISTICS OF ANTITHROMBOTIC MEDICATION	27
2.1. Antithrombotic medication. Definition. Classification.....	27
2.2. Characteristics of anticoagulants.....	27
2.2.1. Direct-acting anticoagulants.....	28
2.2.2. Indirect-acting anticoagulants (antivitamins K).....	33
2.3. Characteristics of antiplatelet drugs.....	36
2.4. Characteristics of fibrinolytic drugs.....	38
2.5. New oral anticoagulants.....	40
<i>CHAPTER 3</i>	46
PARTICULARITIES OF DENTAL TREATMENT IN PATIENTS WITH HEMORRHAGIC SYNDROME	46
3.1. Local hemostatic methods.....	46
3.1.1. Compression dressing.....	46
3.1.2. Wound suturing.....	48
3.1.3. Electrocoagulation of bleeding tissues.....	50
3.1.4. Chemical agents.....	51
3.1.5. Active hemostatic agents.....	52
3.1.5.1. Thrombin.....	52
3.1.5.2. Fibrin glue.....	54
3.1.6. Method of achieving hemostasis in PEB by local application of human thrombin and aminocaproic acid 5 %.....	54
3.1.7. Passive hemostatic agents.....	61
3.1.7.1. Collagen-based products.....	62

3.1.7.2. Oxidized cellulose.....	62
3.1.7.3. Absorbable gelatin sponges.....	63
3.1.7.4. Bone wax.....	64
3.1.8. Properties of an ideal hemostatic agent.....	65
3.2. General treatment of patients with hemorrhagic syndrome.....	66
<i>CHAPTER 4.....</i>	<i>68</i>
PREVENTION OF SEVERE THROMBOEMBOLIC AND EMORRHAGIC ACCIDENTS IN PATIENTS ON ANTITHROMBOTIC THERAPY.....	68
4.1. Preoperative assessment of the hemostatic system.....	68
4.2. The INR value in identifying bleeding and thromboembolic risk.....	70
4.3. Management of surgical interventions in patients on antithrombotic medication.....	73
4.3.1. Peculiarities of dental extraction.....	73
4.3.2. Peculiarities of dental implant placement.....	77
4.4. Management of oral surgery.....	80
<i>CHAPTER 5.....</i>	<i>82</i>
ANTIBIOTIC PROPHYLAXIS IN PATIENTS AT INCREASED RISK OF INFECTIVE ENDOCARDITIS.....	82
5.1. Epidemiological information.....	82
5.2. Risk factors for the development of infective endocarditis.....	82
5.3. Antibacterial prophylaxis regimens.....	83
CONCLUSIONS.....	84
ABBREVIATIONS.....	85
REFERENCES.....	86
ANNEXES.....	98
Annex 1. Coagulation tests in various hemorrhagic diseases.....	98
Annex 2. Questionnaire on the state of the hemostatic system.....	99
Annex 3. Indications for oral anticoagulants, recommended INR values and treatment duration in patients on vitamin K antagonists.....	100
Annex 4. Management of patients on antithrombotic medication requiring oral surgery.....	101
Annex 5. Comorbidities and additional risk factors for the development of infective endocarditis requiring optional prophylaxis.....	102
Anexa 6. Pharmacological properties of new oral anticoagulants.....	103
Anexa 7. Suggested use of NOACs according to patient characteristics.....	104
AUTHORS' BIOGRAPHY.....	105